TriangleNCT00507767 · STUDY IN CONTEXT
Dasatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
Draft scope assessment: unclear. Attached because the study's own record describes recurrent disease. The study was not selected for this indication by its sponsor, and its eligibility has not been reconciled against this page in full. Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.
Read the full study record and all posted results →
Linked outcomes
Reported safety
Quality of life and patient-reported measures
No linked quality-of-life measure is recorded for this setting and study.
Full draft applicability and source-link record
- trial
- release id
- clinical-indications-draft-1
- disease state id
- ds-salivary-gland-cancer-recurrent-79ac7906
- nct id
- NCT00507767
- trial label
- Dasatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
- applicability
- unclear
- applicability note
- Attached because the study's own record describes recurrent disease. The study was not selected for this indication by its sponsor, and its eligibility has not been reconciled against this page in full.
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
- provenance class
- registry-condition-search
- discovery note
- Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.
- outcome Count
- 1
- harms Count
- 1
- qol Count
- 0
- outcomes
- release id
- clinical-indications-draft-1
- disease state id
- ds-salivary-gland-cancer-recurrent-79ac7906
- nct id
- NCT00507767
- outcome key
- om-0000
- source section id
- NCT00507767-om-0000
- source outcome index
- 0
- endpoint
- Number of Participants With Progression-free Survival at 12-weeks
- endpoint definition
- Progression-free survival (PFS) is defined as stable disease or better. Participants who have received at least one dose of dasatinib and who die or leave the study before 12 weeks will be counted as having progressive disease.
- time origin
- At 12-weeks
- analysis role
- primary
- reporting status
- NOT_STATED
- data cutoff
- Source null
- population note
- Analysis per protocol.
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
- arms
- release id
- clinical-indications-draft-1
- disease state id
- ds-salivary-gland-cancer-recurrent-79ac7906
- nct id
- NCT00507767
- outcome key
- om-0000
- arm key
- OG000
- arm label
- Dasatinib
- regimen
- 100 mg orally twice daily
- analyzed count
- 15
- analyzed unit
- Participants
- is comparator
- Source null
- source pointer
- NCT00507767-om-0000#groups/OG000
- harms
- release id
- clinical-indications-draft-1
- disease state id
- ds-salivary-gland-cancer-recurrent-79ac7906
- nct id
- NCT00507767
- harm key
- EG000
- source section id
- NCT00507767-ae
- event group key
- EG000
- event group label
- Dasatinib
- serious affected
- 4
- serious at risk
- 15
- other affected
- 15
- other at risk
- 15
- frequency threshold
- 5
- collection period
- Treatment period three 4-week cycles for total of 12 weeks with follow up every 2 cycles following first cycle. Study data collection period for all participants was 18 months.
- event definition
- Source null
- undenominated note
- Source null
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
- quality of life
- setting source links
Preserved source evidence · Not medical advice